Direct-to-consumer virtual care provider Hims & Hers is strengthening its healthcare capabilities through the acquisition of Trybe Labs, a New Jersey-based at-home laboratory testing facility. The integration aims to enhance patient care by enabling comprehensive whole-body testing and blood draws in the comfort of patients' homes.
The acquisition is set to broaden Hims & Hers' clinical offerings, particularly in areas such as low testosterone treatment and perimenopausal and menopausal support. The company expects to implement these testing capabilities within the next year, marking a significant expansion of its healthcare services portfolio.
Dr. Patrick Carroll, chief medical officer of Hims & Hers, emphasized the company's commitment to modern healthcare delivery: "The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them. This next generation of healthcare is what we're building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them."
The strategic acquisition aligns with Hims & Hers' existing services, which include telehealth consultations, compounded GLP-1 medications, and various prescription and non-prescription health products. The company's platform currently offers products across multiple categories, including general wellness, sexual health, skincare, and hair care, both directly to consumers and through wholesale partnerships.
"Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient," Carroll added. "At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect."
The announcement has positively impacted the company's market performance, with its stock reaching approximately $71.40 per share on the New York Stock Exchange, marking its highest trading value since its public debut via SPAC in 2021. The company is scheduled to release its fourth quarter and full year 2024 earnings report shortly.
Click here for the original news story.